IMR Press / FBL / Volume 27 / Issue 1 / DOI: 10.31083/j.fbl2701034
Open Access Review
Bone health and therapeutic agents in advanced prostate cancer
Show Less
1 Department of Radiation Oncology, Hospital Universitario de Toledo, 45007 Toledo, Spain
2 Department of Radiation Oncology, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain
3 Department of Radiation Oncology, Hospital Universitario Cruces, 48903 Barakaldo, Spain
4 Department of Radiation Oncology, ASCIRES Hospital General Universitario de Valencia, 46014 Valencia, Spain
5 Department of Radiation Oncology, Hospital Vall d´Hebron, 08035 Barcelona, Spain
6 Department of Radiation Oncology, Hospital Universitario Virgen de la Victoria, 29010 Malaga, Spain
7 Department of Radiation Oncology, The Royal Marsden Hospital and Institute of Cancer Research, SM2 5PT Sutton, UK
8 Department of Radiation Oncology, Ghent University Hospital, 9000 Ghent, Belgium
9 Department of Radiation Oncology, Institut Bergonié, 33000 Bordeaux, France
10 Department of Radiation Oncology, Iridium Network, 2610 Antwerp, Belgium
11 Department of Radiation Oncology, Hospital Universitario Quironsalud, Hospital La Luz, Universidad Europea de Madrid, 28223 Madrid, Spain

Academic Editors: Guohui Sun and Graham Pawelec

Front. Biosci. (Landmark Ed) 2022, 27(1), 34; https://doi.org/10.31083/j.fbl2701034
Submitted: 28 October 2021 | Revised: 8 December 2021 | Accepted: 15 December 2021 | Published: 18 January 2022
(This article belongs to the Special Issue Recent Advances in Cancer Research and Environmental Toxicology)
Copyright: © 2022 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.
Abstract

Prostate cancer is the most frequent genitourinary tumor worldwide. Maintaining an optimum bone health throughout the natural course of prostate cancer is an important aspect in the management of this disease, particularly in this at risk population of older and frail patients who experience bone loss related to androgen-deprivation therapy (ADT) and/or patients who develop bone metastases. The number of treatment options for advanced prostate cancer that combine ADT with docetaxel, new hormonal agents and/or radiotherapy has increased substantially in recent years. Bisphosphonates and other bone targeted agents such as denosumab have shown an improvement in bone mineral density and are suited for patients with treatment-related osteoporosis and/or bone metastases with an increased risk of skeletal-related events (SREs). In this context, the aim of this review is to analyse key aspects of bone health and therapies that can prevent the occurrence of SREs throughout the clinical course of prostate cancer, and how to combine them with new available treatments in this setting.

Keywords
Bone health
Prostate cancer
Skeletal-related events
Osteoporosis
Denosumab
Bisphosphonates
Figures
Fig. 1.
Share
Back to top